Understanding Tumors
Sort
ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
A new study co-led by ISB and published in the journal Cell Reports Medicine reveals how a rare lung cancer can shift between cell types, pass through hybrid states, and build distinct tumor “neighborhoods” that may help it evade detection and resist treatment.
ISB Professor Sui Huang challenges the long-held belief that genetic mutations primarily drive cancer, offering a fresh perspective that could revolutionize how we think about and treat this complex disease.
Sui Huang challenges the prevailing view of cancer as purely genetic in a new essay published in PLOS Biology. Huang and colleagues suggest non-genetic factors and disrupted gene regulatory networks may play crucial roles in cancer development.
In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.